Social Media Ideas for Tlry

Should You Buy Tilray Brands Stock Before Oct. 8?

The cannabis company is set to report its earnings early next month.

Tilray Trades Below $5 With Record Fiscal Revenue on the Books. What's Holding the Stock Back?

Tilray Brands has moved beyond marijuana, turning itself into a diversified brand manager.

Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?

The cannabis industry is still finding its footing, but Tilray just posted record revenue with its beverage business turning profitable. Canopy is narrowing losses and targeting po...

Tilray Brands Looks Ready For Another Large Short Squeeze Move

Tilray Brands: Is the Stock a Buy at Less Than $4?

The stock is down big this year, but that doesn't mean it's overdue for a rally.

Tilray's Rescheduling Rally Keeps Fading -- Where Will the Stock Be if Washington Stalls Again?

Don't expect a rebound anytime soon.

3 Huge Red Flags From Tilray's Q1 Earnings Report

The company's top line may have increased, but it doesn't take long for investors to spot problems in its recent earnings report.

2 Cannabis Stocks That Are Quietly Trouncing the Market in 2026

Trulieve and Cronos are turning stronger results into market-beating gains.

Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts

3 Reasons I'm Still Not Buying Tilray Stock -- Even at Penny-Stock Prices

Tilray's stock isn't the bargain it appears to be at first.

2 High-Octane Cannabis Stocks to Buy in October for Aggressive Investors

Innovative Industrial Properties and Trulieve Cannabis may be turning things around.

This Cannabis Stock Jumped 12% in a Day: The Math Says Be Careful

Tilray's record revenue came with declining cannabis sales and negative free cash flow, making the investment much more speculative than the headline suggests. The post This Cannab...

Curaleaf Holdings, Inc. (CURA:CA) Shareholder/Analyst Call Transcript

‘It’s not easy being a Jewish weed brand’: Tokin’ Jew faces uncertain future despite explosive growth

For the past several years, Jewish cannabis company Tokin’ Jew has offered a little something to take the edge off just about every Jewish occasion. High Holidays have you feeling...

Fla. Judge Axes Pot Co.'s THC Patent Suit Against Trulieve

A Florida federal judge on Monday granted cannabis company Trulieve Inc.'s request to toss a rival patent company's complaint alleging Trulieve infringed several of the rival's pat...

BioXcel files for Chapter 11, will sell assets to Teva

Aurora Maintains Shareholder Recommendation to Take No Action at this Time as Curaleaf Has Yet to File Their Revised Hos...

NASDAQ | TSX: ACB

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More

Eli Lilly-backed TRex Bio closes day flat after IPO

TRex Bio prices $117M IPO to support immune drug work

Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.

Sell Recreational Cannabis as "Medicine"- Federal Class Action Alleges a "Concerted Campaign"

The federal governments policy contradiction is unavoidable:The federal government is conferring the legitimacy and financial benefits of Schedule III medicine on state-licensed op...

Curaleaf's Hostile Takeover Attempt of Aurora Cannabis Is Hitting Turbulence. Here's What Investors Should Watch.

Hostile takeovers are called hostile for a reason, and this one is getting ugly.

<![CDATA[Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing ]]>

Liquidia Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Liquidia (LQDA)

LQDA shareholders who lost money after a court found that Yutrepia infringed two valid United Therapeutics patent claims may have the right to seek recovery. The investigation incl...